NCT05186805View on ClinicalTrials.gov

Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

August 24, 2022

Study Completion Date

August 24, 2022

Conditions
Atopic Dermatitis
Interventions
DRUG

Tapinarof cream, 1%

Tapinarof cream, 1% applied topically once daily

Trial Locations (10)

29445

Dermavant Investigative Site, Summerville

33014

Dermavant Investigative Site, Miami Lakes

33016

Dermavant Investigative Site, Hialeah

33146

Dermavant Investigative Site, Coral Gables

60611

Dermavant Investigative Site, Chicago

77030

Dermavant Investigative Site, Houston

78213

Dermavant Investigative Site, San Antonio

80112

Dermavant Investigative Site, Centennial

91320

Dermavant Investigative Site, Thousand Oaks

T3A 2N1

Dermavant Investigative Site, Calgary

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT05186805 - Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis | Biotech Hunter | Biotech Hunter